Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Product Launch

Dr. Reddy's Laboratories Product Launch

Dr. Reddy's Laboratories launched its generic Semaglutide Injection in Canada following Health Canada approval. This marks the first generic Semaglutide authorization in a G7 country.

Source

BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Dr. Reddy's Laboratories Ltd: key numbers

Share price
₹1,335.40
Market cap
₹1,11,463 Cr
Revenue (annual)
₹33,700 Cr
Net profit (annual)
₹4,196 Cr
P/E (TTM)
39.8×Sector 46.1×
Promoter holding
26.63%-0.01% QoQ
FII holding
20.30%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Dr. Reddy's Laboratories Ltd

All →

Other product launch announcements

All →